In the article, “The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications” by Moe et al., published in the January issue (Can J Cardiol 2015; 31:3-16), there is an error on page 12. The recommendation on combined angiotensin/neprilysin inhibition in HFrEF should state an EF of ≤ 40%. A corrected recommendation is provided here.
Recommendation
- 1.We recommend that in patients with mild to moderate HF, an EF ≤ 40%, an elevated NP level or hospitalization for HF in the past 12 months, a serum potassium < 5.2 mmol/L, and an eGFR ≥ 30 mL/min and treated with appropriate doses of guideline-directed medical therapy should be treated with LCZ696 in place of an ACE inhibitor or an angiotensin receptor blocker, with close surveillance of serum potassium and creatinine (Conditional Recommendation; High-Quality Evidence).
Article info
Publication history
Published online: August 27, 2015
Identification
Copyright
© 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial ImplicationsCanadian Journal of CardiologyVol. 31Issue 1
- PreviewThe 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Update provides discussion on the management recommendations on 3 focused areas: (1) anemia; (2) biomarkers, especially natriuretic peptides; and (3) clinical trials that might change practice in the management of patients with heart failure. First, all patients with heart failure and anemia should be investigated for reversible causes of anemia. Second, patients with chronic stable heart failure should undergo natriuretic peptide testing.
- Full-Text
- Preview
